CN114886964B - Traditional Chinese medicine composition for treating drug-induced liver injury and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating drug-induced liver injury and preparation method thereof Download PDFInfo
- Publication number
- CN114886964B CN114886964B CN202210778495.5A CN202210778495A CN114886964B CN 114886964 B CN114886964 B CN 114886964B CN 202210778495 A CN202210778495 A CN 202210778495A CN 114886964 B CN114886964 B CN 114886964B
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- chinese medicine
- parts
- portions
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating drug-induced liver injury and a preparation method thereof, belonging to the technical field of compound traditional Chinese medicines. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 15 to 20 portions of astragalus root, 12 to 15 portions of notoginseng, 15 to 20 portions of liquorice, 5 to 10 portions of schisandra fruit and 5 to 8 portions of tangerine peel. Aiming at a liver cell injury mechanism of DILI, the invention has reasonable composition, takes astragalus root as a monarch drug, pseudo-ginseng and liquorice as ministerial drugs, and schisandra fruit and dried orange peel as adjuvant drugs, and the combination of the drugs plays a role in treating DILI. Compared with the traditional water decoction, the extraction method of the DILI treatment traditional Chinese medicine composition has better treatment effect.
Description
Technical Field
The invention relates to the technical field of compound traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating drug-induced liver injury and a preparation method thereof.
Background
Drug-induced liver injury (DILI) refers to liver injury induced by various prescriptions or non-prescriptions of chemical drugs, biological agents, traditional Chinese Medicines (TCM), natural Medicines (NM), health Products (HP), dietary Supplements (DS), metabolites thereof, and adjuvants. TCM refers to various herbal and non-herbal traditional Chinese medicines, decoction pieces and compound Chinese patent medicines produced and used under the guidance of traditional national medicine theory such as traditional Chinese medicine, NM refers to natural medicinal substances and preparations thereof prepared by applying modern medicine theory and technology. DILI is one of the most common and serious Adverse Drug Reactions (ADRs), and the serious can cause Acute Liver Failure (ALF) and even death. So far, simple, objective and specific diagnosis indexes and specific treatment means are still lacked.
The clinical manifestations of acute DILI are usually nonspecific. The incubation periods are very different, and can be as short as 1 to several days and as long as several months. Most patients have no obvious symptoms, and only the biochemical indexes of the liver such as ALT, AST, ALP, GGT and the like in serum are increased to different degrees. Some patients may have digestive tract symptoms such as hypodynamia, anorexia, aversion to oil, liver distending pain and epigastric discomfort. The patients with obvious cholestasis can have yellow skin, light stool color, pruritus and the like. A few patients may have allergic manifestations such as fever, rash, eosinophilia, and even joint soreness, and may also have other manifestations of extrahepatic organ damage. Chronic DIH can be clinically manifested as chronic hepatitis, liver fibrosis, compensatory and decompensated cirrhosis, AIH-like DILI, chronic intrahepatic bile deposition and bile duct disappearance syndrome (VBDS), and the like.
At present, the effective treatment medicine for DILI in the field of traditional Chinese medicines is ancient-Japanese-ancient-wood-13, but the ancient-Japanese-ancient-wood-13 is not suitable for all people due to the limitation of traditional Chinese medicines contained in the prescription, so that the research on a new traditional Chinese medicine composition capable of effectively treating DILI is necessary, and the widening of the traditional Chinese medicine composition for treating DILI is necessary.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition for treating drug-induced liver injury and a preparation method thereof. Aiming at a liver cell injury mechanism of DILI, the treatment effect of DILI is achieved by using radix astragali as a monarch drug, pseudo-ginseng and liquorice as ministerial drugs and schisandra and dried orange peel as adjuvant drugs which are combined together.
In order to achieve the purpose, the invention provides the following technical scheme:
one of the technical schemes of the invention is as follows: the traditional Chinese medicine composition for treating the drug-induced liver injury comprises the following raw materials in parts by weight: 15 to 20 portions of astragalus root, 12 to 15 portions of notoginseng, 15 to 20 portions of liquorice, 5 to 10 portions of shizandra berry and 5 to 8 portions of dried orange peel.
Preferably, the traditional Chinese medicine composition for treating the drug-induced liver injury comprises the following raw materials in parts by weight: 20 parts of astragalus, 15 parts of pseudo-ginseng, 15 parts of liquorice, 10 parts of schisandra chinensis and 5 parts of dried orange peel.
The second technical scheme of the invention is as follows: provides a preparation method of the traditional Chinese medicine composition for treating the drug-induced liver injury, which comprises the following steps:
pulverizing radix astragali, notoginseng radix, glycyrrhrizae radix, fructus Schisandrae, and pericarpium Citri Tangerinae, mixing to obtain Chinese medicinal mixture, adding ethanol water solution, reflux extracting, concentrating the extractive solution to remove ethanol in the extractive solution to obtain extract, and diluting the extract with water to obtain the Chinese medicinal composition for treating drug-induced hepatic injury.
Preferably, the volume fraction of ethanol in the ethanol aqueous solution is 50-60%.
Preferably, the material-liquid ratio of the traditional Chinese medicine mixture to the ethanol aqueous solution is 1g (10-15) mL.
Preferably, the reflux extraction time is 120-150 min.
Preferably, the water dilution is water dilution until the crude drug content is 1g/mL.
The target cells for DILI damage are mainly hepatocytes, mainly due to the idiosyncratic responses of the body to drugs, including anaphylaxis (immunological idiosyncratic) and metabolism (metabolic idiosyncratic). The former is mainly because the drug or its active metabolite is used as hapten, and combines with endogenous protein to form autoantibody with immunogen, which can induce liver cell death or destruction; the immunogen can also be recognized by CD4+ cells, induces to produce certain cytokines, further activates CD8+ T cells, and causes Fas or perforin-mediated liver cell apoptosis and cell damage. The latter is mainly associated with individual drug metabolism enzyme genetic polymorphism, and has reduced drug metabolism capability, so that drug prototypes or/and intermediate metabolites are accumulated, and toxicity to liver cells is generated.
The invention provides a traditional Chinese medicine composition for treating drug-induced liver injury, which comprises astragalus membranaceus, pseudo-ginseng, liquorice, schisandra chinensis and pericarpium citri reticulatae.
Wherein, the flavone and saponin substances in the astragalus root inhibit the immune function of the organism by inhibiting the induction of IL-2, thereby achieving the treatment effect on the damage of liver cells, and the traditional Chinese medicine is the monarch medicine of the prescription.
Flavones and saponins in Notoginseng radix can inhibit immune-mediated inflammatory reaction, assist radix astragali, and treat liver cell injury; the liquorice has sweet and warm property and flavor, can coordinate the effects of the other drugs and relieve the damage of the drugs to the organism, and is the ministerial drug of the prescription.
Schisanhenol and schisandrin B in fructus Schisandrae can be used for treating liver cell injury by scavenging active oxygen free radicals in organism; tangerine peel, pericarpium Citri Reticulatae is an adjuvant drug of the recipe for improving circulation and regulating qi.
The formula provided by the invention achieves the treatment effect on liver cell injury mainly through the action of inhibiting the organism immunity, and mainly plays a role through flavone, saponin and phenolic substances in the traditional Chinese medicines (the flavone substances in the astragalus and the pseudo-ginseng can not only inhibit the organism immunity, but also play a role in resisting free radicals and are also beneficial to the treatment of DILI), so that an alcohol extraction method is selected during extraction, the effect is to fully extract target components in the traditional Chinese medicines, and simultaneously, the extraction effect on polysaccharide in the traditional Chinese medicines is reduced (most polysaccharides in the traditional Chinese medicines have the effect of enhancing the organism immunity, and liquid medicine with high polysaccharide content can influence the treatment effect). By adopting the alcohol extraction method, the curative effect of the traditional Chinese medicine composition on DILI can be enhanced.
The invention has the following beneficial technical effects:
the invention provides a traditional Chinese medicine composition capable of treating DILI (DiLI), aiming at a liver cell damage mechanism of DILI, the traditional Chinese medicine composition is reasonable in formula, astragalus is used as a monarch drug, pseudo-ginseng and liquorice are used as ministerial drugs, and schisandra and dried orange peel are used as adjuvant drugs, and the traditional Chinese medicine composition is used together to play a role in treating DILI.
The invention also provides an extraction method of the DILI treatment traditional Chinese medicine composition, which comprises the steps of extracting effective components in the traditional Chinese medicines by adopting an ethanol water solution, removing ethanol in an extracting solution by concentration, and adding water for dilution to prepare the DILI traditional Chinese medicine composition extracting solution. Compared with the traditional water decoction, the liquid medicine extracted by the invention has better treatment effect.
Detailed Description
Reference will now be made in detail to various exemplary embodiments of the invention, the detailed description should not be construed as limiting the invention but rather as a more detailed description of certain aspects, features and embodiments of the invention. It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
Further, for numerical ranges in this disclosure, it is understood that each intervening value, between the upper and lower limit of that range, is also specifically disclosed. Every intervening value, to the extent any stated value or intervening value in a stated range, and any other stated or intervening value in a stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention.
As used herein, the terms "comprising," "including," "having," "containing," and the like are open-ended terms that mean including but not limited to.
Example 1
(1) Respectively crushing 20 parts of astragalus membranaceus, 15 parts of pseudo-ginseng, 15 parts of liquorice, 10 parts of schisandra chinensis and 5 parts of dried orange peel by using a plant crusher, crushing and mixing;
(2) Adding 60% ethanol aqueous solution into the mixture according to the feed-liquid ratio of 1g to 15mL, heating to boil, condensing, refluxing and extracting for 120min, cooling and filtering;
(3) Concentrating the filtrate to 1/10 of the original volume to obtain traditional Chinese medicine extract, and diluting the extract with water until the crude drug content is 1g/mL to obtain the traditional Chinese medicine composition for treating drug-induced liver injury.
Example 2
(1) Respectively crushing 15 parts of astragalus, 15 parts of pseudo-ginseng, 18 parts of liquorice, 8 parts of schisandra and 6 parts of dried orange peel by using a plant crusher, crushing and mixing;
(2) Adding 60% ethanol aqueous solution into the mixture according to the feed-liquid ratio of 1g;
(3) Concentrating the filtrate to 1/10 of the original volume to obtain traditional Chinese medicine extract, and diluting the extract with water until the crude drug content is 1g/mL to obtain the traditional Chinese medicine composition for treating drug-induced liver injury.
Example 3
(1) Respectively crushing 15 parts of astragalus, 12 parts of pseudo-ginseng, 20 parts of liquorice, 5 parts of schisandra and 8 parts of dried orange peel by using a plant crusher, crushing and mixing;
(2) Adding ethanol water solution with volume fraction of 60% into the mixture according to the feed liquid ratio of 1g;
(3) Concentrating the filtrate to 1/10 of the original volume to obtain traditional Chinese medicine extract, and diluting the extract with water until the crude drug content is 1g/mL to obtain the traditional Chinese medicine composition for treating drug induced liver injury.
Comparative example 1
(1) Respectively crushing 20 parts of astragalus membranaceus, 15 parts of pseudo-ginseng, 15 parts of liquorice, 10 parts of schisandra chinensis and 5 parts of dried orange peel by using a plant crusher, crushing and mixing;
(2) Adding purified water into the mixture according to a material-liquid ratio of 1g.
Test example 1
35C 57/BL6 mice were divided into a blank group, a model group, a treatment group, an example 1 group, an example 2 group, an example 3 group and a comparative example 1 group, each group consisting of 5 mice. Wherein the mice in the model group, the treatment group, the example 1 group, the example 2 group, the example 3 group and the comparative example 1 group are intraperitoneally injected with 20mg/mL of acetaminophen (APAP) every day at a dose of 500mg/kg, and the mice in the blank group are injected with an equal volume of physiological saline; the mice in the group of example 1, the group of example 2, the group of example 3 and the group of comparative example 1 were respectively subjected to gavage with the prepared traditional Chinese medicine composition liquid for treating drug-induced liver injury (the prepared liquid medicine is diluted by 100 times, and the diluted liquid medicine is gavage at a dose of 10 mL/kg), the mice in the treatment group were subjected to gavage with 2g/kg of Gougu-13, and the other groups were subjected to gavage with physiological saline of the same volume. After 2 weeks, each group of mice was subjected to canthus blood sampling, serum was isolated, and ALT and AST contents in serum were measured using ALT and AST enzyme-linked immunosorbent assay kits, and the measurement results are shown in table 1.
TABLE 1 serum ALT and AST contents of each group of mice
| ALT content (U/L) | AST content (U/L) | |
| Blank group | 32.22±5.77** | 145.75±11.32** |
| Model set | 153.54±21.06 | 354.98±32.69 |
| Treatment group | 129.93±19.57** | 315.54±33.16** |
| EXAMPLE 1 group | 125.77±23.08** | 307.03±34.71** |
| EXAMPLE 2 group | 96.74±24.90** | 280.44±26.59** |
| EXAMPLE 3 group | 77.32±18.73** | 241.13±27.51** |
| Comparative example 1 group | 69.02±17.37** | 226.47±21.33** |
Remarking: in table 1, P < 0.05 compared to the model group; * Denotes P < 0.01 compared to the model group.
As can be seen from Table 1, compared with the blank group, the serum contents of ALT and AST of the model group mice are obviously increased, which indicates that a liver cell injury model is successfully constructed; compared with the model group, the ALT and AST contents in the blood serum of the mice are obviously reduced in the groups of examples 1-3 and the group of comparative example 1, which shows that the traditional Chinese medicine formula provided by the invention has a treatment effect on drug-induced liver injury; meanwhile, compared with a treatment group, the treatment effect of the groups of the embodiments 1 to 3 is better, which shows that the formula provided by the invention has better curative effect than the traditional formula for treating DILI; by comparing the group 1 with the group 1, it can be seen that the Chinese medicinal liquid obtained by the preparation method of the present invention has better therapeutic effect compared with the conventional decoction.
The above-described embodiments are merely illustrative of the preferred embodiments of the present invention, and do not limit the scope of the present invention, and various modifications and improvements of the technical solutions of the present invention can be made by those skilled in the art without departing from the spirit of the present invention, and the technical solutions of the present invention are within the scope of the present invention defined by the claims.
Claims (7)
1. A traditional Chinese medicine composition for treating drug-induced liver injury is characterized by comprising the following raw material components in parts by weight: 15 to 20 portions of astragalus, 12 to 15 portions of pseudo-ginseng, 15 to 20 portions of liquorice, 5 to 10 portions of schisandra and 3242 portions of dried orange peel 5~8.
2. The traditional Chinese medicine composition for treating drug-induced liver injury according to claim 1, which is characterized by comprising the following raw material components in parts by weight: 20 parts of astragalus, 15 parts of pseudo-ginseng, 15 parts of liquorice, 10 parts of schisandra chinensis and 5 parts of dried orange peel.
3. A method for preparing the traditional Chinese medicine composition for treating the drug-induced liver injury according to claim 1 or 2, which is characterized by comprising the following steps:
pulverizing radix astragali, notoginseng radix, glycyrrhrizae radix, fructus Schisandrae, and pericarpium Citri Tangerinae, mixing to obtain Chinese medicinal mixture, adding ethanol water solution, reflux extracting, concentrating the extractive solution to obtain extract, and diluting the extract with water to obtain the Chinese medicinal composition for treating drug induced hepatic injury.
4. The method according to claim 3, wherein the volume fraction of ethanol in the aqueous ethanol solution is 50 to 60%.
5. The preparation method according to claim 3, wherein the feed-liquid ratio of the traditional Chinese medicine mixture to the ethanol aqueous solution is 1g (10 to 15) mL.
6. The method according to claim 3, wherein the reflux extraction is carried out for 120 to 150min.
7. The method according to claim 3, wherein the dilution with water is a dilution with water until the crude drug content is 1g/mL.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210778495.5A CN114886964B (en) | 2022-07-04 | 2022-07-04 | Traditional Chinese medicine composition for treating drug-induced liver injury and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210778495.5A CN114886964B (en) | 2022-07-04 | 2022-07-04 | Traditional Chinese medicine composition for treating drug-induced liver injury and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114886964A CN114886964A (en) | 2022-08-12 |
| CN114886964B true CN114886964B (en) | 2023-04-14 |
Family
ID=82729415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210778495.5A Active CN114886964B (en) | 2022-07-04 | 2022-07-04 | Traditional Chinese medicine composition for treating drug-induced liver injury and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114886964B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1537607A (en) * | 2003-08-29 | 2004-10-20 | 李清成 | Traditional Chinese medicine for removing heat from liver to reduce transaminase |
-
2022
- 2022-07-04 CN CN202210778495.5A patent/CN114886964B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN114886964A (en) | 2022-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Puri | Rasayana: Ayurvedic herbs for longevity and rejuvenation | |
| CN101357219B (en) | Medicine for treating chronic hepatitis B | |
| MXPA03003446A (en) | Novel medicinal herbal composition for treating liver diseases and hiv. | |
| CN101239112B (en) | Chinese medicinal composition for regulating blood fat and preparation thereof | |
| WO2021169026A1 (en) | Traditional chinese medicine composition for preventing epidemics, and preparation method therefor and use thereof | |
| CN108524814A (en) | A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose | |
| CN102114099B (en) | Traditional Chinese medicine preparation for inhibiting liver cancer and preparation method thereof | |
| CN110075216B (en) | Food composition with auxiliary blood fat reducing, weight losing and liver protecting effects and preparation method, preparation and application thereof | |
| CN101804103B (en) | Drug for treating leukopenia caused by concurrent chemoradiotherapy of malignant tumor and preparation method thereof | |
| CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
| Li | Chinese herbal medicine | |
| CN110478452B (en) | Traditional Chinese medicine composition for treating gout and preparation method thereof | |
| CN110339320B (en) | Traditional Chinese medicine composition for treating fatty liver | |
| CN114886964B (en) | Traditional Chinese medicine composition for treating drug-induced liver injury and preparation method thereof | |
| CN114796392B (en) | Traditional Chinese medicine composition for treating gout and application thereof | |
| Sharif et al. | Anti-asthmatic effect of Juglans regia Linn. in mice. | |
| CN101120977B (en) | Medicine for treating tumor | |
| CN115634275A (en) | Traditional Chinese medicine preparation for treating liver cancer liver stagnation and spleen deficiency stasis toxin syndrome | |
| CN115252753A (en) | Traditional Chinese medicine composition for treating insomnia and application thereof | |
| CN104042895A (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof | |
| CN108096528B (en) | Traditional Chinese medicine composition for enhancing sensitivity of esophageal cancer to chemotherapeutic drugs and application thereof | |
| CN113069505A (en) | Medicinal diet beverage for improving immunity and preparation method thereof | |
| CN105596890A (en) | Method for preparing traditional Chinese medicine composition for treating lung cancer | |
| CN109999158A (en) | A kind of pharmaceutical composition and its application for treating lung cancer | |
| CN108339051A (en) | A kind of drug that treating chemical damage, preparation method and applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |